(PharmaNewsWire.Com, April 06, 2017 ) The Autoimmune Monoclonal Antibodies Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape. According to the report, the Autoimmune Monoclonal Antibodies Market is projected to reach USD 25,274.7 million by 2021, at a CAGR of 7.84% from 2016 to 2021.
Irregular functioning of humans immune system results in autoimmune disorders. Overproduction of self-reactive immune cells (such as antibodies & T-cells) damage regular functions of /cells/tissues/organs. This lead to different autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and others diseases. Typically, drugs are used as a treatment to cure autoimmune disorders. The adverse effects associated with drugs has made switched to concentrate on monoclonal antibodies.
Monoclonal antibodies have the ability to offer less toxic and more efficient therapeutic alternatives to treat autoimmune diseases. Recent years have seen the emergence of monoclonal antibodies being used to treat wide array of diseases that are related to immune response. These antibodies are mono-specific comprising of identical immune cells which are clones of a single parent cell and are directed towards a specific cellular target. Thus monoclonal antibodies due to its customizable nature can be used to treat the self-reactive immune cells.
Global Autoimmune Monoclonal Antibodies market is expected to witness growth owing to growing research & development to stimulate the development of monoclonal antibodies rising number of patients with autoimmune diseases, and increasing public & private organizations involvement to support advanced therapeutics development. In addition, rising demand for antibody-based therapeutics, increasing adoption of advanced healthcare therapeutics, and growing number of lifestyle associated disorders are further promoting the growth of global autoimmune monoclonal antibodies.
The key players in global Autoimmune Monoclonal Antibodies market include, GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), Johnson & Johnson (U.S.), Innovent Biologics, Inc. (China), Takeda Pharmaceutical Company Ltd. (Japan), Amgen Inc. (U.S.), Biogen Inc.(U.S.), and UCB Company (Belgium).
About Market Data Forecast: Market Data Forecast is a firm working in the areas of market research and business intelligence. We have rich experience in research across major industry segments like Healthcare, Agriculture, Food & Beverages etc. and we cater to the needs of both individual and corporate clients. Our research services contribute to key business areas like business process improvement, key decision making and developing an appropriate corporate strategy. We are truly committed to our clients and other stakeholders for providing customized research services of the highest quality all the while being an organization thats trusted for its integrity, respected for its accountability, and admired for its excellence, by both clients and competitors alike.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
